The pharmaceutical niche player Algor released startling fourth-quarter projections this week, a reversal of fortunes many in financial circles attribute to the company renaming many of its medications for the treatment of sexually transmitted diseases. Realizing that social embarrassment may play a part in the afflicted avoiding treatment for their cursed states, Algor saw fourth-quarter sales of their best selling herpes treatment ClearVue skyrocket after the drug was changed from its longstanding name of HerpEase.

Finally bending to pressure from marketing experts, Algor has begun renaming its other not-quite-popular-enough drugs under the now commonplace industry practice of drug names that have nothing to do with a condition or its treatment. By the beginning of 2005, the company hopes to offer a complete line of attractively-named treatments for the unfortunately STDed.

GonorRid, the company’s industry-standard drug for the treatment of puss-laden malcontents suffering from gonorrhea, will be shipped to pharmacies under its new label of SmoothOperator beginning in January.

A similar fate awaits the company’s pride and joy, Crabex, Algor’s floundering treatment for pubic lice. After months of focus group testing, Algor has recently decided to rename the drug PartyZone.

Last but not least is SyphiLess, the company’s breakthrough treatment for syphilis sufferers. Though Algor has yet to make an official announcement on the renaming of this drug, early leaked reports indicate that the drug will be called either Blissex or PissFree in 2005.

But will Algor’s new approach be a success? To answer that question, we went straight to STD sufferers for the real dirt.

“Oh yeah, I’d definitely buy more if it was named something like Smurfies or something, that would definitely boost sales,” according to porn impresario Tori Anus, a frequent Crabex user. “Then I’d stop getting those dirty looks from the dried up old bags at the Wal-Mart pharmacy. They’d just think I’d been fucking Smurfs or something.”

Determined to dig deeper into the beans of the story, this reporter conducted further research among the loose women of 1-900-HOT-DATE, likely to be experts on the treatment of cock-borne illness. In addition to providing hours or stimulating conversation, Misty and Chakra also provided great advice about writing off the cost of the toll call as a business expense.

“Algor definitely has a hot idea on their hands there,” insisted Misty, a buxom brunette with smoldering green eyes. “You’re getting me hot just talking about it.”

“Hot and naughty,” agreed Chakra, a Thai-Scottish delight who insisted on conducting the telephone interview in the nude.

No doubt the executives at Algor have done similar research, since it’s loads more fun than the alternative of company execs experimentally contracting STDs themselves to see if they feel embarrassed about getting treatment. So the New Year looks to be a happy one for Algor shareholders, who haven’t heard news this good since the company changed its name from Cock Rot Ltd. in 1999, amid reports that investors were too embarrassed to purchase their stock.